Luigi Janiri
Research Subjects
Research Interests
Luigi Janiri has a total of 452 co-authors. Here are the top co-authors by number of shared publications:
- Marco Di Nicola
University Policlinic Foundation “A. Gemelli” IRCSS-Catholic University of the Sacred Heart, Largo Agostino Gemelli, 8, 00136 Rome, Italy
60 shared publications - Marianna Mazza
Department of Neuroscience, Head-Neck and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy
44 shared publications Giovanni Martinotti
Department of Neuroscience and Imaging, Institute of Psychiatry, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy
36 shared publicationsPietro Bria
Institute of Psychiatry and Psychology, Catholic University of the Sacred Heart, Rome, Italy
29 shared publications- Gabriele Sani
Department of Neuroscience, Head-Neck and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy
17 shared publications Massimo Di Giannantonio
Department of Neuroscience and Imaging, " G. d'Annunzio" University, Chieti, Italy
17 shared publications
Latest Publications
- Open Access
Catching the Storm Before It Breaks: Advancing Early Diagnosis and Intervention in Bipolar Disorder
In recent years, growing attention has been directed toward the early diagnosis and intervention of bipolar disorder (BD), driven by the recognition that timely clinical action may significantly alter the trajectory of the illness. Early identification of individuals at risk, as well as intervention during prodromal or subthreshold phases, offers the potential to delay onset, reduce episode severity, improve long-term outcomes, and possibly prevent the full manifestation of the disorder. This narrative review aims to provide a comprehensive overview of the current literature on the early stages of BD, including clinical high-risk states, neurobiological and cognitive markers, and psychosocial indicators. It also explores the latest research findings and their implications for clinical practice, highlighting the importance of integrated approaches that combine biomarker discovery, risk stratification models, and youth-focused mental health services. Finally, the review discusses the ethical and practical challenges of early intervention and underscores the need for further longitudinal studies and personalized preventive strategies.
Open AccessCatching the Storm Before It Breaks: Advancing Early Diagnosis and Intervention in Bipolar Disorder
In recent years, growing attention has been directed toward the early diagnosis and intervention of bipolar disorder (BD), driven by the recognition that timely clinical action may significantly alter the trajectory of the illness. Early identification of individuals at risk, as well as intervention during prodromal or subthreshold phases, offers the potential to delay onset, reduce episode severity, improve long-term outcomes, and possibly prevent the full manifestation of the disorder. This narrative review aims to provide a comprehensive overview of the current literature on the early stages of BD, including clinical high-risk states, neurobiological and cognitive markers, and psychosocial indicators. It also explores the latest research findings and their implications for clinical practice, highlighting the importance of integrated approaches that combine biomarker discovery, risk stratification models, and youth-focused mental health services. Finally, the review discusses the ethical and practical challenges of early intervention and underscores the need for further longitudinal studies and personalized preventive strategies.
- Open Access
- 21 November 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (12) , 1768
Eco-Anxiety and Mental Health: Correlates of Climate Change Distress
Background. Climate change is increasingly recognized as a threat to mental health, giving rise to constructs such as eco-anxiety and solastalgia. Although these phenomena have gained attention, quantitative data from European populations remain scarce. Objectives. This study investigated the prevalence and correlates of eco-anxiety in an Italian sample, focusing on associations with demographics, environmental disaster exposure, psychological distress, psychosis-risk indicators, and quality of life. Methods. A cross-sectional online survey was conducted with 1051 participants. Measures included the Hogg Eco-Anxiety Scale (HEAS-13), Brief Symptom Inventory (BSI), Prodromal Questionnaire (PQ-16), SF-36 Health Survey, and a socio-demographic/environmental exposure questionnaire. Data were analyzed using correlations, t-tests, and regression analyses. Results. Eco-anxiety was higher among younger participants, women, and individuals without children, while education showed a weak negative association. No differences emerged by rural vs. urban residence. Participants exposed to floods, droughts, wildfires, and landslides reported elevated eco-anxiety. Scores correlated strongly with general distress (r = 0.57), positively with psychosis-risk indicators (PQ-16 distress, r = 0.42), and negatively with quality of life (r = −0.25). Conclusions. Eco-anxiety in Italy is linked to socio-demographic vulnerabilities, disaster exposure, and impaired mental health. These findings highlight eco-anxiety as a pressing public health concern and stress the need for prevention and interventions that promote adaptive coping and engagement with climate change.
- 21 November 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (12) , 1768
Open AccessEco-Anxiety and Mental Health: Correlates of Climate Change Distress
Background. Climate change is increasingly recognized as a threat to mental health, giving rise to constructs such as eco-anxiety and solastalgia. Although these phenomena have gained attention, quantitative data from European populations remain scarce. Objectives. This study investigated the prevalence and correlates of eco-anxiety in an Italian sample, focusing on associations with demographics, environmental disaster exposure, psychological distress, psychosis-risk indicators, and quality of life. Methods. A cross-sectional online survey was conducted with 1051 participants. Measures included the Hogg Eco-Anxiety Scale (HEAS-13), Brief Symptom Inventory (BSI), Prodromal Questionnaire (PQ-16), SF-36 Health Survey, and a socio-demographic/environmental exposure questionnaire. Data were analyzed using correlations, t-tests, and regression analyses. Results. Eco-anxiety was higher among younger participants, women, and individuals without children, while education showed a weak negative association. No differences emerged by rural vs. urban residence. Participants exposed to floods, droughts, wildfires, and landslides reported elevated eco-anxiety. Scores correlated strongly with general distress (r = 0.57), positively with psychosis-risk indicators (PQ-16 distress, r = 0.42), and negatively with quality of life (r = −0.25). Conclusions. Eco-anxiety in Italy is linked to socio-demographic vulnerabilities, disaster exposure, and impaired mental health. These findings highlight eco-anxiety as a pressing public health concern and stress the need for prevention and interventions that promote adaptive coping and engagement with climate change.
- Open Access
Neural Pathways of Visual Face Recognition Immediately After Birth
The present study aimed to investigate the electrophysiological correlates of face-identity recognition in newborn infants immediately after birth. Electroencephalographic acquisition was continuously recorded in 23 newborn infants (3 < age < 24 h of life) during the following visual task: presentation of a woman’s face for 60 s (“known face”); random presentation of 50 known faces, 50 novel women’s faces, and 50 chessboards (for 2 s each). The final sample included in ERP analyses was composed of 11 newborn infants (male/female: 6/5; age: 5 h 16′ ± 3 h 51′). A greater negative amplitude of the N290 and smaller P400 and LC2 were found in response to the known face compared with the novel one in the left hemisphere. A shorter N290 latency was detected during the known face presentation compared with the novel one, and a longer latency of the same component was observed during novel face presentation compared with the chessboard. These findings suggest that newborns process a face differently from an object at birth and that they can discriminate a new face from a familiar one previously viewed for one minute.
Open AccessNeural Pathways of Visual Face Recognition Immediately After Birth
The present study aimed to investigate the electrophysiological correlates of face-identity recognition in newborn infants immediately after birth. Electroencephalographic acquisition was continuously recorded in 23 newborn infants (3 < age < 24 h of life) during the following visual task: presentation of a woman’s face for 60 s (“known face”); random presentation of 50 known faces, 50 novel women’s faces, and 50 chessboards (for 2 s each). The final sample included in ERP analyses was composed of 11 newborn infants (male/female: 6/5; age: 5 h 16′ ± 3 h 51′). A greater negative amplitude of the N290 and smaller P400 and LC2 were found in response to the known face compared with the novel one in the left hemisphere. A shorter N290 latency was detected during the known face presentation compared with the novel one, and a longer latency of the same component was observed during novel face presentation compared with the chessboard. These findings suggest that newborns process a face differently from an object at birth and that they can discriminate a new face from a familiar one previously viewed for one minute.
- 25 May 2023
- Published by Springer Nature in Acta Diabetologica
- Vol. 60 (8) , 1117-1118
Response to letter to Editor on “DIA2PSI” study
- 25 May 2023
- Published by Springer Nature in Acta Diabetologica
- Vol. 60 (8) , 1117-1118
Response to letter to Editor on “DIA2PSI” study
- Open Access
- 27 March 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (4) , 817
The Nrf2 Pathway in Depressive Disorders: A Systematic Review of Animal and Human Studies
There is increasing interest in the involvement of antioxidative systems in protecting from depression. Among these, Nrf2 occupies a central place. We aimed to review the role of Nrf2 in depression. For this reason, we conducted a PubMed search using as search strategy (psychiatr*[ti] OR schizo*[ti] OR psychot*[ti] OR psychos*[ti] OR depress*[ti] OR MDD[ti] OR BD[ti] OR bipolar[ti] OR Anxiety[ti] OR antidepress*[ti] OR panic[ti] OR obsess*[ti] OR compulsio*[ti] OR “mood disord*”[ti] OR phobi*[ti] OR agoraphob*[ti] OR anorex*[ti] OR anorect*[ti] OR bulimi*[ti] OR “eating disorder*”[ti] OR neurodevelopm*[ti] OR retardation[ti] OR autism[ti] OR autistic[ti] OR ASM[ti] OR adhd[ti] OR “attention-deficit”[ti]) AND nrf2, which on the 9th of March produced 208 results of which 89 were eligible for our purposes. Eligible articles were studies reporting data of Nrf2 manipulations or content by any treatment in human patients or animals with any animal model of depression. Most studies were on mice only (N = 58), 20 on rats only, and three on both rats and mice. There were two studies on cell lines (in vitro) and one each on nematodes and fish. Only four studies were conducted in humans, one of which was post mortem. Most studies were conducted on male animals; however, human studies were carried out on both men and women. The results indicate that Nrf2 is lower in depression and that antidepressant methods (drugs or other methods) increase it. Antioxidant systems and plasticity-promoting molecules, such as those in the Nrf2–HO-1, BDNF–TrkB, and cyclic AMP–CREB pathways, could protect from depression, while glycogen synthase kinase-3β and nuclear factor κB oppose these actions, thus increasing depressive-like behaviours. Since Nrf2 is also endowed with tumorigenic and atherogenic potential, the balance between benefits and harms must be taken into account in designing novel drugs aiming at increasing the intracellular content of Nrf2.
- 27 March 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (4) , 817
Open AccessThe Nrf2 Pathway in Depressive Disorders: A Systematic Review of Animal and Human Studies
There is increasing interest in the involvement of antioxidative systems in protecting from depression. Among these, Nrf2 occupies a central place. We aimed to review the role of Nrf2 in depression. For this reason, we conducted a PubMed search using as search strategy (psychiatr*[ti] OR schizo*[ti] OR psychot*[ti] OR psychos*[ti] OR depress*[ti] OR MDD[ti] OR BD[ti] OR bipolar[ti] OR Anxiety[ti] OR antidepress*[ti] OR panic[ti] OR obsess*[ti] OR compulsio*[ti] OR “mood disord*”[ti] OR phobi*[ti] OR agoraphob*[ti] OR anorex*[ti] OR anorect*[ti] OR bulimi*[ti] OR “eating disorder*”[ti] OR neurodevelopm*[ti] OR retardation[ti] OR autism[ti] OR autistic[ti] OR ASM[ti] OR adhd[ti] OR “attention-deficit”[ti]) AND nrf2, which on the 9th of March produced 208 results of which 89 were eligible for our purposes. Eligible articles were studies reporting data of Nrf2 manipulations or content by any treatment in human patients or animals with any animal model of depression. Most studies were on mice only (N = 58), 20 on rats only, and three on both rats and mice. There were two studies on cell lines (in vitro) and one each on nematodes and fish. Only four studies were conducted in humans, one of which was post mortem. Most studies were conducted on male animals; however, human studies were carried out on both men and women. The results indicate that Nrf2 is lower in depression and that antidepressant methods (drugs or other methods) increase it. Antioxidant systems and plasticity-promoting molecules, such as those in the Nrf2–HO-1, BDNF–TrkB, and cyclic AMP–CREB pathways, could protect from depression, while glycogen synthase kinase-3β and nuclear factor κB oppose these actions, thus increasing depressive-like behaviours. Since Nrf2 is also endowed with tumorigenic and atherogenic potential, the balance between benefits and harms must be taken into account in designing novel drugs aiming at increasing the intracellular content of Nrf2.
- Open Access
- 25 January 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (2) , 211
Depressive Symptoms during Pregnancy: Prevalence and Correlates with Affective Temperaments and Psychosocial Factors
Pregnancy is a unique experience in women’s life, requiring a great ability of adaptation and self-reorganization; vulnerable women may be at increased risk of developing depressive symptoms. This study aimed to examine the incidence of depressive symptomatology during pregnancy and to evaluate the role of affective temperament traits and psychosocial risk factors in predicting them. We recruited 193 pregnant women, collected data regarding sociodemographic, family and personal clinical variables, social support and stressful life events and administered the Mood Disorder Questionnaire (MDQ), the Patient Health Questionnaire-9 (PHQ-9), and the Temperament Evaluation of Memphis, Pisa, Paris and San Diego-Autoquestionnaire (TEMPS-A). In our sample, prevalence of depressive symptomatology was 41.45% and prevalence of depression was 9.85% (6.75% mild and 3.10% moderate depression). We have chosen a cutoff >4 on PHQ-9 to identify mild depressive symptoms which may predict subsequent depression. Statistically significant differences between the two groups were found in the following factors: gestational age, occupation, partner, medical conditions, psychiatric disorders, family psychiatric history, stressful life events, and TEMPS-A mean scores. In our sample mean scores on all affective temperaments but the hyperthymic, were significantly lower in the control group. Only depressive and hyperthymic temperaments were found to be, respectively, risk and protective factors for depressive symptomatology. The current study confirms the high prevalence and complex aetiology of depressive symptomatology during pregnancy and suggests that affective temperament assessment seems to be a useful adjunctive instrument to predict depressive symptomatology during pregnancy and postpartum.
- 25 January 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (2) , 211
Open AccessDepressive Symptoms during Pregnancy: Prevalence and Correlates with Affective Temperaments and Psychosocial Factors
Pregnancy is a unique experience in women’s life, requiring a great ability of adaptation and self-reorganization; vulnerable women may be at increased risk of developing depressive symptoms. This study aimed to examine the incidence of depressive symptomatology during pregnancy and to evaluate the role of affective temperament traits and psychosocial risk factors in predicting them. We recruited 193 pregnant women, collected data regarding sociodemographic, family and personal clinical variables, social support and stressful life events and administered the Mood Disorder Questionnaire (MDQ), the Patient Health Questionnaire-9 (PHQ-9), and the Temperament Evaluation of Memphis, Pisa, Paris and San Diego-Autoquestionnaire (TEMPS-A). In our sample, prevalence of depressive symptomatology was 41.45% and prevalence of depression was 9.85% (6.75% mild and 3.10% moderate depression). We have chosen a cutoff >4 on PHQ-9 to identify mild depressive symptoms which may predict subsequent depression. Statistically significant differences between the two groups were found in the following factors: gestational age, occupation, partner, medical conditions, psychiatric disorders, family psychiatric history, stressful life events, and TEMPS-A mean scores. In our sample mean scores on all affective temperaments but the hyperthymic, were significantly lower in the control group. Only depressive and hyperthymic temperaments were found to be, respectively, risk and protective factors for depressive symptomatology. The current study confirms the high prevalence and complex aetiology of depressive symptomatology during pregnancy and suggests that affective temperament assessment seems to be a useful adjunctive instrument to predict depressive symptomatology during pregnancy and postpartum.
- Open Access
- 2 January 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (1) , 104
COVID-19 and New-Onset Psychosis: A Comprehensive Review
Psychosis is a multifactorial condition that typically involves delusions, hallucinations, and disorganized thought, speech or behavior. The observation of an association between infectious epidemics and acute psychosis dates back to the last century. Recently, concerns have been expressed regarding COVID-19 and the risk for the development of new-onset psychosis. This article reviewed the current evidence of a possible link between SARS-CoV-2 and risk of psychosis as an acute or post-infectious manifestation of COVID-19. We here discuss potential neurobiological and environmental factors as well as a number of challenges in ascribing a causal pathogenic relationship between SARS-CoV-2 infection and new-onset psychosis.
- 2 January 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (1) , 104
Open AccessCOVID-19 and New-Onset Psychosis: A Comprehensive Review
Psychosis is a multifactorial condition that typically involves delusions, hallucinations, and disorganized thought, speech or behavior. The observation of an association between infectious epidemics and acute psychosis dates back to the last century. Recently, concerns have been expressed regarding COVID-19 and the risk for the development of new-onset psychosis. This article reviewed the current evidence of a possible link between SARS-CoV-2 and risk of psychosis as an acute or post-infectious manifestation of COVID-19. We here discuss potential neurobiological and environmental factors as well as a number of challenges in ascribing a causal pathogenic relationship between SARS-CoV-2 infection and new-onset psychosis.
- Open Access
- 7 November 2022
- Published by Springer Nature in Acta Diabetologica
- Vol. 60 (2) , 247-255
Evaluation of the prevalence of the most common psychiatric disorders in patients with type 2 diabetes mellitus using the patient health questionnaire: results of the cross-sectional “DIA2PSI” study
Aims: Common Psychiatric Disorders (CPDs) are associated with the development of overweight and obesity, the strongest risk factors for the onset and maintenance of Type 2 Diabetes mellitus (T2D). To the best of our knowledge, this is the first study to assess the prevalence of CPDs in patients with T2D in Italy. Methods: This is a monocentric cross-sectional study; n = 184 T2D patients were screened for CPDs using the Patient Health Questionnaire (PHQ). Primary outcome was to evaluate the prevalence of CPDs. To assess association between CPDs and risk factors, we have utilized univariable logistic regression models. Results: 64.1% were men, median age was 67 (59–64) and median BMI 27 (25–30) kg/m2. The 42.9% tested positive for one or more mental disorders, 25.6% for depression. Patients with higher BMI (p = 0.04) had an increased likelihood of testing positive to the PHQ. Patients who had implemented lifestyle changes (p < 0.01) and were aware that mental health is linked to body health (p = 0.07) had a reduction in the likelihood of testing positive. Conclusions: Prevalence of CPDs in T2D patients is higher than in the general population. Since CPDs favor the onset and subsistence of T2D, integrated diabetic-psychiatric therapy is required for improvement or remission of T2D in patients with comorbid CPDs.
- 7 November 2022
- Published by Springer Nature in Acta Diabetologica
- Vol. 60 (2) , 247-255
Open AccessEvaluation of the prevalence of the most common psychiatric disorders in patients with type 2 diabetes mellitus using the patient health questionnaire: results of the cross-sectional “DIA2PSI” study
Aims: Common Psychiatric Disorders (CPDs) are associated with the development of overweight and obesity, the strongest risk factors for the onset and maintenance of Type 2 Diabetes mellitus (T2D). To the best of our knowledge, this is the first study to assess the prevalence of CPDs in patients with T2D in Italy. Methods: This is a monocentric cross-sectional study; n = 184 T2D patients were screened for CPDs using the Patient Health Questionnaire (PHQ). Primary outcome was to evaluate the prevalence of CPDs. To assess association between CPDs and risk factors, we have utilized univariable logistic regression models. Results: 64.1% were men, median age was 67 (59–64) and median BMI 27 (25–30) kg/m2. The 42.9% tested positive for one or more mental disorders, 25.6% for depression. Patients with higher BMI (p = 0.04) had an increased likelihood of testing positive to the PHQ. Patients who had implemented lifestyle changes (p < 0.01) and were aware that mental health is linked to body health (p = 0.07) had a reduction in the likelihood of testing positive. Conclusions: Prevalence of CPDs in T2D patients is higher than in the general population. Since CPDs favor the onset and subsistence of T2D, integrated diabetic-psychiatric therapy is required for improvement or remission of T2D in patients with comorbid CPDs.
- Open Access
- 28 September 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (10) , 1598
Depressive Symptoms in Expecting Fathers: Is Paternal Perinatal Depression a Valid Concept? A Systematic Review of Evidence
Background. Since the identification of Couvade syndrome in the late 1950s, little attention has been dedicated to the issue of depression in expecting fathers. Objective. To quantify the extent of depression in expecting fathers and find out if they match their pregnant partners’ depression. Methods. We conducted a PubMed and ClinicalTrials.gov search using paternal depression and all its variants as terms. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement to include eligible studies. Results. We identified a grand total of 1443 articles, of which 204 were eligible. The total number of fathers/expecting fathers involved was 849,913. Longitudinal studies represented more than half of the included studies; more than three-quarters of the studies used the Edinburgh Postnatal Depression Scale (EPDS). The average occurrence of paternal depression was around 5%, which confers the entity some clinical dignity. Depression tends to occur more in expecting women and new mothers than in expecting partners or new fathers, while the co-occurrence in the same couple is quite low. Limitations. The methodological heterogeneity of the included studies prevents us from meta-analyzing the obtained data. The validity of the instruments used is another issue. Conclusions. Paternal depression is distinct from maternal depression and occurs at lower rates (about half). The very existence of a paternal depression clinical entity is beyond any doubt. Future research should address methodological heterogeneity.
- 28 September 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (10) , 1598
Open AccessDepressive Symptoms in Expecting Fathers: Is Paternal Perinatal Depression a Valid Concept? A Systematic Review of Evidence
Background. Since the identification of Couvade syndrome in the late 1950s, little attention has been dedicated to the issue of depression in expecting fathers. Objective. To quantify the extent of depression in expecting fathers and find out if they match their pregnant partners’ depression. Methods. We conducted a PubMed and ClinicalTrials.gov search using paternal depression and all its variants as terms. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement to include eligible studies. Results. We identified a grand total of 1443 articles, of which 204 were eligible. The total number of fathers/expecting fathers involved was 849,913. Longitudinal studies represented more than half of the included studies; more than three-quarters of the studies used the Edinburgh Postnatal Depression Scale (EPDS). The average occurrence of paternal depression was around 5%, which confers the entity some clinical dignity. Depression tends to occur more in expecting women and new mothers than in expecting partners or new fathers, while the co-occurrence in the same couple is quite low. Limitations. The methodological heterogeneity of the included studies prevents us from meta-analyzing the obtained data. The validity of the instruments used is another issue. Conclusions. Paternal depression is distinct from maternal depression and occurs at lower rates (about half). The very existence of a paternal depression clinical entity is beyond any doubt. Future research should address methodological heterogeneity.
- Open Access
- 16 June 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (12) , 7397
Trazodone Prolonged-Release Monotherapy in Cannabis Dependent Patients during Lockdown Due to COVID-19 Pandemic: A Case Series
(1) Background: During the SARS-CoV-2 (COVID-19) pandemic, cannabis use increased relative to pre-pandemic levels, while forced home confinement frequently caused sleep/wake cycle disruptions, psychological distress, and maladaptive coping strategies with the consequent appearance of anxiety symptoms and their potential impact on substance use problems. (2) Aim: Long-acting trazodone (150 mg or 300 mg daily) has a potential benefit as monotherapy in patients with cannabis use disorder. The present work aims to investigate the effectiveness of trazodone in optimizing the condition of people with cannabis dependence under pandemic conditions. (3) Methods: All cases with cannabis use disorder were uniformly treated with long-acting trazodone 150 mg or 300 mg/day; their craving and clinical status were monitored through appropriate psychometric scales. Side effects were recorded as they were reported by patients. We described the cases of three young patients—one man and two women—who were affected by chronic cannabis use disorder and who experienced lockdown-related psychological distress and sought psychiatric help. (4) Results: The described cases highlight that the once-a-day formulation of trazodone seems to have a therapeutic role in patients with cannabis use disorder and to guarantee tolerability and efficacy over time. No significant side effects emerged. (5) Conclusions: The use of long-acting trazodone (150 mg or 300 mg daily) has a potential benefit as monotherapy in patients with cannabis use disorder. Trazodone deserves to be studied in terms of its efficacy for cannabis use disorder.
- 16 June 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (12) , 7397
Open AccessTrazodone Prolonged-Release Monotherapy in Cannabis Dependent Patients during Lockdown Due to COVID-19 Pandemic: A Case Series
(1) Background: During the SARS-CoV-2 (COVID-19) pandemic, cannabis use increased relative to pre-pandemic levels, while forced home confinement frequently caused sleep/wake cycle disruptions, psychological distress, and maladaptive coping strategies with the consequent appearance of anxiety symptoms and their potential impact on substance use problems. (2) Aim: Long-acting trazodone (150 mg or 300 mg daily) has a potential benefit as monotherapy in patients with cannabis use disorder. The present work aims to investigate the effectiveness of trazodone in optimizing the condition of people with cannabis dependence under pandemic conditions. (3) Methods: All cases with cannabis use disorder were uniformly treated with long-acting trazodone 150 mg or 300 mg/day; their craving and clinical status were monitored through appropriate psychometric scales. Side effects were recorded as they were reported by patients. We described the cases of three young patients—one man and two women—who were affected by chronic cannabis use disorder and who experienced lockdown-related psychological distress and sought psychiatric help. (4) Results: The described cases highlight that the once-a-day formulation of trazodone seems to have a therapeutic role in patients with cannabis use disorder and to guarantee tolerability and efficacy over time. No significant side effects emerged. (5) Conclusions: The use of long-acting trazodone (150 mg or 300 mg daily) has a potential benefit as monotherapy in patients with cannabis use disorder. Trazodone deserves to be studied in terms of its efficacy for cannabis use disorder.